StreetInsider.com News Articles

Form 8-K Biohaven Ltd. For: Oct 08

Thu, 15 Oct 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20261015/27194190.html

Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

Fri, 09 Oct 2026 07:05:55 -0400

Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst commented: "This morning (10/8), BHVN announced that it is out-licensing its 1300-series immunoglobulin G (IgG) degraders to Ono Pharmaceuticals in Japan, South Korea, Taiwan, and Association of Southeast Asian Nations (ASEAN) countries. For this, BHVN will receive $80mn in cash upfront, $20mn in milestones anticipated within a year after close, and ~20% royalties on eventual net sales in those regions. Recall the company's MoDE (molecular degrader of extracellular proteins) IgG degraders include lead-candidate BHV-1300 (in Phase 3 for Graves' disease), and BHV-1310/1320

Citi reiterates Buy rating on Biohaven Pharma after licensing deal

Thu, 08 Oct 2026 09:52:42 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $17.00 price target on Biohaven Pharma (NYSE: BHVN) following the company's announcement of a regional licensing agreement with Ono Pharmaceutical.

Under the deal, Ono Pharmaceutical receives rights to Biohaven's MoDE pan-IgG degrader portfolio, including lead asset BHV-1300 and next-generation candidates BHV-1310 and BHV-1320, across Japan, South Korea, Taiwan, and ASEAN markets. Biohaven retains rights in the U.S., Europe, China, and the rest of the world.

The agreement provides Biohaven with up to $100M in near-term capital, consisting of an $80M upfront payment and a potential $20M milestone payment within one year, along with

Raymond James Reiterates Strong Buy Rating on Biohaven Pharma (BHVN)

Thu, 08 Oct 2026 09:50:54 -0400

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $30.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst comments "Remain Strong Buy rated on BHVN shares following the company’s announcement to outlicense the rights to IgG degrader BHV-1300 in Japan to Ono Pharma, which brings in $100M in near-term cash ($80M at deal close and $20M in a milestone payment anticipated within a year). We have written extensively about Biohaven’s financing overhang (see notes here and here), and we viewed Biohaven’s deal in August to out-license BHV-7000 to SK Biopharma as a key catalyst for reducing this overhang.

Biohaven licenses IgG degrader portfolio to Ono for $100M

Thu, 08 Oct 2026 04:00:24 -0400

Biohaven Ltd. (NYSE: BHVN) has entered into a licensing agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN member states, according to a press release.

Under the agreement, Biohaven will receive $80 million at closing and is eligible for an additional $20 million milestone payment anticipated within a year, bringing potential near-term payments to $100 million. Biohaven will also receive royalties of approximately 20% on net sales within the licensed territory. Biohaven retains all rights outside the licensed territory, including

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Thu, 08 Oct 2026 04:00:00 -0400

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Thu, 08 Oct 2026 04:00:00 -0400

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive

Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation

Mon, 28 Sep 2026 07:31:29 -0400

Biohaven Ltd. (NYSE: BHVN) announced that Phase 1 clinical data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC), have been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 18-20, 2026, in Barcelona, Spain.
BHV-1530 uses Biohaven's proprietary topoisomerase I (TopoIx) payload and is being studied in the ongoing BHV1530-101 trial (NCT06874335), a Phase 1, first-in-human, open-label, multicenter study evaluating the drug as monotherapy and in combination with cemiplimab in adults with advanced or metastatic solid tumors. The presentation is scheduled for November 19, 2026, during Plenary Session 3.
According to

Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation

Mon, 28 Sep 2026 07:31:29 -0400

Biohaven Ltd. (NYSE: BHVN) announced that Phase 1 clinical data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC), have been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 18-20, 2026, in Barcelona, Spain.
BHV-1530 uses Biohaven's proprietary topoisomerase I (TopoIx) payload and is being studied in the ongoing BHV1530-101 trial (NCT06874335), a Phase 1, first-in-human, open-label, multicenter study evaluating the drug as monotherapy and in combination with cemiplimab in adults with advanced or metastatic solid tumors. The presentation is scheduled for November 19, 2026, during Plenary Session 3.
According to

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Mon, 28 Sep 2026 07:30:00 -0400

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.

First-in-class FGFR3 ADC: BHV-1530

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Mon, 28 Sep 2026 07:30:00 -0400

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.

First-in-class FGFR3 ADC: BHV-1530

Citi reiterates buy rating on Biohaven Pharma amid rival's trial pause

Fri, 18 Sep 2026 05:17:10 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $17.00 price target on Biohaven Pharma (NYSE: BHVN).
The call follows competitor Xenon's decision to voluntarily pause new enrollment in its ongoing trials for major depressive disorder and bipolar depression after identifying neuropsychiatric adverse events in a larger psychiatry dataset of its drug azetukalner, including dizziness, somnolence, confusion, and psychosis-related events.
Semenkow noted that Biohaven's drug opakalim has shown different tolerability data, with updated open-label extension data showing somnolence and dizziness rates of 3% and 4%, respectively, and a 95% patient rollover rate into the extension study. Biohaven is not pursuing major depressive

Form 4 Biohaven Ltd. For: Sep 15 Filed by: Gentile Kimberly

Thu, 17 Sep 2026 18:15:00 -0400
si-local-file:///var/storage/secattach/20260917/27077036.html

H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

Fri, 11 Sep 2026 06:59:28 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $10.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst commented: "Today, Biohaven disclosed in an 8-K that the FDA issued a partial clinical hold on September 4 pausing new patient enrollment across the opakalim (BHV-7000) program after nonclinical testing identified a metabolite with uncertain relevance to humans. The hold applies only to new enrollment, and dosing continues for the more than 600 patients already randomized across the program. BHV7000-303, the fully enrolled pivotal focal-epilepsy study, remains on track for top-line data in the second half of 2026. Dosing in the

Baird Reiterates Outperform Rating on Biohaven Pharma (BHVN), "no change to outlook"

Thu, 10 Sep 2026 10:14:47 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $42.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst commented: "No change to outlook on regulatory update. Biohaven announced a partial clinical hold on the opakilim program following findings of certain metabolites identified during rodent testing. Dosing of already-enrolled patients can continue, so this doesn't impact the readout timeline RISE3 pivotal study in FOS (topline on track for 2H26). New patients can't be enrolled until clarifying nonclinical studies can characterize the specific metabolite, but we view this as a fairly common and quickly resolvable issue, and therefore not likely to impact

Biohaven stock tumbles after pausing trial enrollment

Thu, 10 Sep 2026 07:26:58 -0400

Investing.com -- Biohaven Ltd. (NYSE:BHVN) shares fell 17% Thursday morning after the company paused new patient enrollment in its BHV-7000 clinical trials following a partial clinical hold issued by the U.S. Food and Drug Administration.
The FDA instructed the company to halt new enrollment pending additional nonclinical studies related to a specific metabolite of BHV-7000 observed in rodent testing, according to a company filing. The agency determined there was insufficient information to assess risks of the metabolite to human subjects at this time and issued the partial clinical hold letter on September 4, 2026.
The hold applies only to new patient enrollment,

Biohaven stock tumbles after pausing trial enrollment

Thu, 10 Sep 2026 07:26:58 -0400

Investing.com -- Biohaven Ltd. (NYSE:BHVN) shares fell 17% Thursday morning after the company paused new patient enrollment in its BHV-7000 clinical trials following a partial clinical hold issued by the U.S. Food and Drug Administration.
The FDA instructed the company to halt new enrollment pending additional nonclinical studies related to a specific metabolite of BHV-7000 observed in rodent testing, according to a company filing. The agency determined there was insufficient information to assess risks of the metabolite to human subjects at this time and issued the partial clinical hold letter on September 4, 2026.
The hold applies only to new patient enrollment,

Biohaven stock tumbles after pausing trial enrollment

Thu, 10 Sep 2026 07:26:58 -0400

Investing.com -- Biohaven Ltd. (NYSE:BHVN) shares fell 17% Thursday morning after the company paused new patient enrollment in its BHV-7000 clinical trials following a partial clinical hold issued by the U.S. Food and Drug Administration.
The FDA instructed the company to halt new enrollment pending additional nonclinical studies related to a specific metabolite of BHV-7000 observed in rodent testing, according to a company filing. The agency determined there was insufficient information to assess risks of the metabolite to human subjects at this time and issued the partial clinical hold letter on September 4, 2026.
The hold applies only to new patient enrollment,

Biohaven stock tumbles after pausing trial enrollment

Thu, 10 Sep 2026 07:26:58 -0400

Investing.com -- Biohaven Ltd. (NYSE:BHVN) shares fell 17% Thursday morning after the company paused new patient enrollment in its BHV-7000 clinical trials following a partial clinical hold issued by the U.S. Food and Drug Administration.
The FDA instructed the company to halt new enrollment pending additional nonclinical studies related to a specific metabolite of BHV-7000 observed in rodent testing, according to a company filing. The agency determined there was insufficient information to assess risks of the metabolite to human subjects at this time and issued the partial clinical hold letter on September 4, 2026.
The hold applies only to new patient enrollment,

Biohaven stock tumbles after pausing trial enrollment

Thu, 10 Sep 2026 07:26:58 -0400

Investing.com -- Biohaven Ltd. (NYSE:BHVN) shares fell 17% Thursday morning after the company paused new patient enrollment in its BHV-7000 clinical trials following a partial clinical hold issued by the U.S. Food and Drug Administration.
The FDA instructed the company to halt new enrollment pending additional nonclinical studies related to a specific metabolite of BHV-7000 observed in rodent testing, according to a company filing. The agency determined there was insufficient information to assess risks of the metabolite to human subjects at this time and issued the partial clinical hold letter on September 4, 2026.
The hold applies only to new patient enrollment,

Form 8-K Biohaven Ltd. For: Sep 04

Thu, 10 Sep 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260910/27044641.html

RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform

Tue, 08 Sep 2026 02:19:22 -0400

RBC Capital analyst Leonid Timashev downgraded Biohaven Pharma (NYSE: BHVN) from Outperform to Sector Perform with a price target of $19.00 (from $23.00).
The analyst comments: “We had been looking for the Kv7 program to provide an upside catalyst and bridge the gap to additional data from the degraders, helping balance the overall risk profile. With shares up ~100% since the lows earlier this year, we think this has largely occurred, as the Kv7 deal has strengthened the balance sheet enabling BHVN to have line of sight to future readouts. From here, we still see longer term upside, but balanced by

RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform

Tue, 08 Sep 2026 02:19:22 -0400

RBC Capital analyst Leonid Timashev downgraded Biohaven Pharma (NYSE: BHVN) from Outperform to Sector Perform with a price target of $19.00 (from $23.00).
The analyst comments: “We had been looking for the Kv7 program to provide an upside catalyst and bridge the gap to additional data from the degraders, helping balance the overall risk profile. With shares up ~100% since the lows earlier this year, we think this has largely occurred, as the Kv7 deal has strengthened the balance sheet enabling BHVN to have line of sight to future readouts. From here, we still see longer term upside, but balanced by

Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

Fri, 28 Aug 2026 08:10:26 -0400

Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst commented: "Yesterday (8/26), BHVN announced that it is outlicensing opakalim for focal epilepsy to SK Biopharmaceuticals. BHVN will receive $400mn in cash ($350mn upfront, $50mn a year after closing), $150mn in development/regulatory milestones and future royalties, and $245mn to buy out BHVN's obligations to Knopp Biosciences (from which BHVN acquired opakalim). Recall that opakalim (a Kv7 activator) has a somewhat de-risked mechanism (competitor Xenon's product has solid data) and could be best-in-class based on its safety/tolerability. Importantly, we are waiting for Phase

H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

Thu, 27 Aug 2026 07:07:33 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $10.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst commented: "Today, Biohaven announced a global licensing and collaboration agreement granting SK Biopharmaceuticals (326030.KS; Not rated) an exclusive worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), in Phase 2/3 development for focal epilepsy. Biohaven receives $400M in cash consideration, $350M at closing and $50M one year later, is eligible for up to $150M in development and regulatory milestones, and will receive tiered royalties in the mid-teens to low twenties on US net sales of opakalim and mid-single-digit